Wen Kou1,2, Jasleen K Sodhi1,3, Xin'an Wu2, Leslie Z Benet4. 1. Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California, 94143-0912, USA. 2. Department of Pharmacy, The First Affiliated Hospital of Lanzhou University, 1 Donggang Road, Chengguan District, Lanzhou, Gansu, China. 3. Department of Drug Metabolism and Pharmacokinetics, Plexxikon Inc., Berkeley, California, USA. 4. Department of Bioengineering and Therapeutic Sciences, Schools of Pharmacy and Medicine, University of California San Francisco, San Francisco, California, 94143-0912, USA. Leslie.Benet@ucsf.edu.
Abstract
PURPOSE: The involvement of the intestinally expressed xenobiotic transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in rivaroxaban disposition based on in vitro studies, similar to what had previously been proposed for apixaban. We recently showed that these efflux transporters were not clinically relevant for apixaban disposition and examine here their relevance for this second Factor Xa inhibitor. METHODS: Using recently published methodologies to discern metabolic- from transporter- mediated drug interactions, a critical evaluation was undertaken of 9 rivaroxaban studies reporting 12 DDIs, one study of food effects and one study of hepatic function. RESULTS: Rationale examination of these clinical studies using basic pharmacokinetic theory finds little support for the clinical significance of intestinal efflux transporters in rivaroxaban disposition. Drug-drug interactions are most likely adequately predicted based on the level of CYP 3A metabolism. CONCLUSION: These analyses indicate that inhibition of efflux transporters appears to have negligible, clinically insignificant effects on the rivaroxaban absorption process, which is consistent with the concern that predictions based on in vitro measures may not translate to a clinically relevant interaction in vivo. We emphasize the need to evaluate gastric emptying, dissolution and other processes related to absorption when using MAT changes to indicate efflux transporter inhibition.
PURPOSE: The involvement of the intestinally expressed xenobiotic transporters P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) have been implicated in rivaroxaban disposition based on in vitro studies, similar to what had previously been proposed for apixaban. We recently showed that these efflux transporters were not clinically relevant for apixaban disposition and examine here their relevance for this second Factor Xa inhibitor. METHODS: Using recently published methodologies to discern metabolic- from transporter- mediated drug interactions, a critical evaluation was undertaken of 9 rivaroxaban studies reporting 12 DDIs, one study of food effects and one study of hepatic function. RESULTS: Rationale examination of these clinical studies using basic pharmacokinetic theory finds little support for the clinical significance of intestinal efflux transporters in rivaroxaban disposition. Drug-drug interactions are most likely adequately predicted based on the level of CYP 3A metabolism. CONCLUSION: These analyses indicate that inhibition of efflux transporters appears to have negligible, clinically insignificant effects on the rivaroxaban absorption process, which is consistent with the concern that predictions based on in vitro measures may not translate to a clinically relevant interaction in vivo. We emphasize the need to evaluate gastric emptying, dissolution and other processes related to absorption when using MAT changes to indicate efflux transporter inhibition.
Entities:
Keywords:
Bioavailability; complex drug-drug interactions; mean absorption time; rivaroxaban
Authors: Yi Zhang; Anshul Gupta; Honggang Wang; Lin Zhou; R Robert Vethanayagam; Jashvant D Unadkat; Qingcheng Mao Journal: Pharm Res Date: 2005-11-01 Impact factor: 4.200
Authors: S Neuhoff; P Langguth; C Dressler; T B Andersson; C G Regårdh; H Spahn-Langguth Journal: Int J Clin Pharmacol Ther Date: 2000-04 Impact factor: 1.366
Authors: Harry R Buller; Anthonie W A Lensing; Martin H Prins; Giancarlo Agnelli; Alexander Cohen; Alexander S Gallus; Frank Misselwitz; Gary Raskob; Sebastian Schellong; Annelise Segers Journal: Blood Date: 2008-07-11 Impact factor: 22.113